Emyria's Michael Winlo discusses with Proactive the news they've started dosing participants in a clinical trial comparing EMD-RX5, its proprietary capsule of ultra-pure CBD, with the currently available Epidyolex. The biotech’s Phase 1 clinical trial will assess the safety and bioavailability of EMD-RX5 against Epidyolex, which is the sole CBD-only medicine formally registered with the TGA and the FDA. In a recent pharmacokinetic animal study, EMD-RX5 showed greater peak concentration and improved bioavailability compared to the equivalent dose of Epidyolex over a 24-hour period.
Emyria begins dosing in clinical trial for symptoms of psychological distress
